Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development
December 04 2017 - 4:30PM
Business Wire
New Addition to Senior Leadership Team
Brings to Cellectis In-Depth Corporate Strategy Expertise within
the Pharmaceutical and MedTech Industries
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS -
Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused
on developing immunotherapies based on gene-edited allogeneic CAR
T-cells (UCART), announced today that the Company has appointed
Elsy Boglioli to the role of Executive Vice President, Strategy and
Corporate Development. Ms. Boglioli’s responsibilities include
directing the long-term strategy and current business priorities of
Cellectis to ensure that the overall mission of the Company is
fulfilled. Ms. Boglioli joins Cellectis from Boston Consulting
Group (BCG), where she served as Partner and Managing Director, and
leader of BCG’s biotech-focused business in Europe.
“Ms. Boglioli’s extensive experience working with leading
pharmaceutical companies, along with her in-depth expertise on
portfolio and innovation strategies across the board, will be
particularly vital for Cellectis as we continue along the path to
market for our game-changing allogeneic CAR T-cell product
candidates,” said Dr. André Choulika, Cellectis CEO. “We look
forward to having her on board during this pivotal time in the
Company’s history so that we can bring a transformative new type of
cancer care to patients in need across the globe as quickly and
efficiently as possible.”
Ms. Boglioli has far-reaching expertise within the pharma and
medtech industries, focusing on everything from corporate strategy
and M&A to research. At BCG, she was also a member of the
global biopharma leadership team and global strategy practice
management team and served as regional head of the strategy
practice for Europe.
“As off-the-shelf immunotherapies have such enormous potential
to advance cancer treatment today, I jumped at the chance to join
Cellectis, as the Company is not only developing a next-generation
cure for cancer, but it’s also truly defining the future of care as
we know it today,” added Ms. Boglioli. “This is all about creating
products that are both cost-effective and available to patients all
over the world, which will ultimately create a fundamental shift in
how we approach medicine moving forward.”
Ms. Boglioli graduated from Ecole Polytechnique in Paris, France
and holds a master’s degree in economy and management from Pompeu
Fabra University in Barcelona, Spain.
About Cellectis
Cellectis is a clinical-stage biopharmaceutical company focused
on developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 17 years of
expertise in gene editing – built on its flagship TALEN® technology
and pioneering electroporation system PulseAgile – Cellectis uses
the power of the immune system to target and eradicate cancer
cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on
the NYSE Alternext market (ticker: ALCLS). To find out more about
us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group.
Disclaimer
This press release contains “forward-looking” statements that
are based on our management’s current expectations and assumptions
and on information currently available to management.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Further information on the risks
factors that may affect company business and financial performance,
is included in filings Cellectis makes with the Security Exchange
Commission from time to time and its financial reports. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
###
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171204006088/en/
For further information, please contact:Media
contacts:CellectisJennifer Moore, 917-580-1088VP of
Communicationsmedia@cellectis.comorKCSA Strategic
CommunicationsCaitlin Kasunich,
212-896-1241ckasunich@kcsa.comorIR contact:CellectisSimon
Harnest, 646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2023 to Apr 2024